Whalegun
Home

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $50K for lobbying in Q1 2023 · Health Issues

Trade details

Type
Lobbying report
Amount
$50,000
Quarter
Q1 2023
Stock
Ultragenyx Pharmaceutical RARE
Client
Ultragenyx Pharmaceutical
Reported
23/04/17

Up 0.0% from last quarter

What else happened in Ultragenyx Pharmaceutical around then

Filed or reported within 30 days of the trade day · 23/03/01~23/04/30

Ultragenyx Pharmaceutical's other lobbying reports

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $50K for lobbying in Q1 2023 · Health Issues | Whalegun